July 29, 2016 5:04 AM ET


Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic therapeutics for the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome, as well as in Phase IIb clinical trial for the treatment of hyperphosphatemia or elevated serum phosphorus levels in patients with end-stage renal disease. The company is also developing RDX022, an oral, non-absorbed potassium-binder for the treatment of hyperkalemia or elevated serum potassium. Its drug candidates in earlier stages of research and development include RDX0...

34175 Ardenwood Boulevard

Suite 200

Fremont, CA 94555

United States

Founded in 2007

61 Employees





Key Executives for Ardelyx, Inc.

Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $470.0K
Chief Financial Officer and Principal Accounting Officer
Age: 48
Total Annual Compensation: $320.0K
Senior Vice President and General Counsel
Age: 52
Total Annual Compensation: $300.0K
Chief Scientific Officer and Executive Vice President
Age: 47
Total Annual Compensation: $132.1K
Compensation as of Fiscal Year 2015.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. - Special Call

To provide update regarding its ongoing Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia for end-stage renal disease (ESRD) patients on dialysis

Ardelyx, Inc. Presents at JMP Securities 2016 Life Sciences Conference, Jun-22-2016 10:30 AM

Ardelyx, Inc. Presents at JMP Securities 2016 Life Sciences Conference, Jun-22-2016 10:30 AM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States.

Ardelyx, Inc. Appoints Robert Bazemore as Member of its Board of Directors and Member of the Compensation Committee of the Board

On June 2, 2016, Ardelyx, Inc. appointed Robert Bazemore, effective immediately, to serve in Class III until the 2017 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. In connection with Mr. Bazemore's appointment, the Board increased the authorized number of members of the Board from six to seven members. Following Mr. Bazemore's appointment, Class III consists of Gordon Ringold, Ph.D., Richard Rodgers, and Mr. Bazemore. Mr. Bazemore was also appointed to serve as a member of the Compensation Committee of the Board (the Compensation Committee). Following Mr. Bazemore's appointment, the Compensation Committee consists of David Mott, as chairman, Dr. Ringold, Mr. Rodgers, and Mr. Bazemore.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
July 15, 2016

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.